Marvel Biosciences Corp. (MRVL.V)
| Previous Close | 0.1050 |
| Open | 0.1050 |
| Bid | 0.1000 x N/A |
| Ask | 0.1100 x N/A |
| Day's Range | 0.1000 - 0.1050 |
| 52 Week Range | 0.0750 - 0.2300 |
| Volume | |
| Avg. Volume | 19,058 |
| Market Cap | 3.979M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1400 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Baystreet
Stocks in play: Marvel Biosciences Corp
Announces that it has successfully completed a multi-kilogram scale run under current good manufacturing ...
- Newsfile
Marvel Biosciences Completes a Critical Manufacturing Milestone Required to Enter Phase 1 Human Trials Targeting Alzheimer's Disease and Depression
Calgary, Alberta--(Newsfile Corp. - January 6, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company " or "Marvel "), are pleased to announce that it has successfully completed a multi-kilogram scale run under current good manufacturing practices ("cGMP") of the active pharmaceutical ingredient (API) of the Company's lead asset MB-204 in partnership with Zhejiang Ausun Pharmaceutical Co., Ltd. ("Ausun"). The cGMP mater
- Newsfile
Marvel Biosciences Successfully Completes its Short Term Dose Ranging Study in Rats and Dogs for MB-204
Calgary, Alberta--(Newsfile Corp. - January 3, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has successfully completed its dose-ranging toxicology studies in rats and dogs, for its lead drug candidate MB-204. These studies will assist in determining the doses for the IND-enabling 4-week GLP toxicology studies."We are looking forward to initiating the 4-week toxicol
